Building a better future for people with rare diseases in all four UK nationsHow has rare disease care changed over the last few years? And what might we expect from the Share XBuilding a better future for people with rare diseases in all four UK nationshttps://pharmaphorum.com/views-analysis-patients/building-a-better-future-for-people-with-rare-diseases-in-all-four-uk-nations/
Rare disease insights from the patient communityTo help pharma companies understand what life is really like for patients with a rare disease, a new Share XRare disease insights from the patient communityhttps://pharmaphorum.com/views-and-analysis/rare-disease-insights-from-the-patient-community/
2021 market access prospects for Spain2021 will be the year when big market access changes – including the far wider use of health Share X2021 market access prospects for Spainhttps://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-spain/
2021 market access prospects for GermanyThe market access landscape in Germany is particularly interesting in 2021, as a key component – AMNOG – Share X2021 market access prospects for Germanyhttps://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-germany/
Common but not normal: It’s time to talk about maternal mental healthAs part of our Patients Insights series, the founder and CEO of Motherhood Understood shares her experience of Share XCommon but not normal: It’s time to talk about maternal mental healthhttps://pharmaphorum.com/views-analysis-patients/common-but-not-normal-its-time-to-talk-about-maternal-mental-health/
West Africa prepares for Ebola vaccination programAmidst the COVID-19 pandemic, West Africa is facing a new outbreak of Ebola. A global emergency stockpile of Share XWest Africa prepares for Ebola vaccination programhttps://pharmaphorum.com/views-and-analysis/west-africa-prepares-for-ebola-vaccination-program/
Pharma’s pipeline continues to provide drama as investors look beyond COVID in Q4While the pandemic has been the focus of R&D attention for much of 2020, that is slowly beginning Share XPharma’s pipeline continues to provide drama as investors look beyond COVID in Q4https://pharmaphorum.com/r-d/views-analysis-r-d/pharmas-pipeline-continues-to-provide-drama-as-investors-look-beyond-covid-in-q4/
No cooling off for pharma digital transformation in 2021COVID-19 has already proved to be a digital accelerant for the pharmaceutical industry, sparking new ideas into life Share XNo cooling off for pharma digital transformation in 2021https://pharmaphorum.com/views-analysis-digital/no-cooling-off-for-pharma-digital-transformation-in-2021/
Reality Check | Is Your Current Customer Engagement Solution the Best Choice for All Markets?Do your sales reps drive a Ferrari? Probably not. Would they like one if you offered it to them? Probably. Once they were used Share XReality Check | Is Your Current Customer Engagement Solution the Best Choice for All Markets?https://pharmaphorum.com/views-analysis-sales-marketing/is-your-customer-engagement-solution-the-best-choice-for-all-markets/